Overview An Open Label Extension Study of the Safety and Clinical Utility of IPX066 in Subjects With Parkinson's Disease Status: Completed Trial end date: 2011-10-01 Target enrollment: Participant gender: Summary The purpose of this study is to determine the long term safety and clinical utility of IPX066 in subjects with Parkinson's Disease. Phase: Phase 3 Details Lead Sponsor: IMPAX Laboratories, Inc.Impax Laboratories, LLCTreatments: CarbidopaCarbidopa, levodopa drug combinationLevodopa